These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 1699088)

  • 1. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA; Joen MC; van Oeveren W; Roozendaal KJ; Harder MP; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass.
    Avidan MS; Levy JH; van Aken H; Feneck RO; Latimer RD; Ott E; Martin E; Birnbaum DE; Bonfiglio LJ; Kajdasz DK; Despotis GJ
    J Thorac Cardiovasc Surg; 2005 Jul; 130(1):107-13. PubMed ID: 15999048
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
    van Oeveren W; Harder MP; Roozendaal KJ; Eijsman L; Wildevuur CR
    J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
    Fish KJ; Sarnquist FH; van Steennis C; Mitchell RS; Hilberman M; Jamieson SW; Linet OI; Miller DC
    J Thorac Cardiovasc Surg; 1986 Mar; 91(3):436-42. PubMed ID: 3512919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy.
    Feindt P; Volkmer I; Seyfert U; Huwer H; Kalweit G; Gams E
    Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ; Segal H; Yacoub M
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP; Haddon WS; Rothberger HK; Mills SA; Rogers AT; Bean VE; Buss DH; Prough DS; Cordell AR
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The influence of preoperative anticoagulation on heparin response during cardiopulmonary bypass.
    Dietrich W; Spannagl M; Schramm W; Vogt W; Barankay A; Richter JA
    J Thorac Cardiovasc Surg; 1991 Oct; 102(4):505-14. PubMed ID: 1833592
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W; Spannagl M; Boehm J; Hauner K; Braun S; Schuster T; Busley R
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coagulation and fibrinolysis system in aortic surgery under deep hypothermic circulatory arrest with aprotinin: the importance of adequate heparinization.
    Okita Y; Takamoto S; Ando M; Morota T; Yamaki F; Matsukawa R; Kawashima Y
    Circulation; 1997 Nov; 96(9 Suppl):II-376-81. PubMed ID: 9386127
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients.
    Huyzen RJ; Harder MP; Huet RC; Boonstra PW; Brenken U; van Oeveren W
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):153-6. PubMed ID: 7515704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B; Englberger L; Gygax E; Nydegger U; Carrel T
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of high-dose aprotinin on anticoagulation, heparin requirement, and celite- and kaolin-activated clotting time in heparin-pretreated patients undergoing open-heart surgery. A double-blind, placebo-controlled study.
    Dietrich W; Dilthey G; Spannagl M; Jochum M; Braun SL; Richter JA
    Anesthesiology; 1995 Oct; 83(4):679-89; discussion 29A-30A. PubMed ID: 7574046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
    Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
    J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ; van Oeveren W; Wei F; Stellingwerf P; Boonstra PW; Gu YJ
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose postoperative aprotinin reduces mediastinal drainage and blood product use in patients undergoing primary coronary artery bypass grafting who are taking aspirin: a prospective, randomized, double-blind, placebo-controlled trial.
    Alvarez JM; Jackson LR; Chatwin C; Smolich JJ
    J Thorac Cardiovasc Surg; 2001 Sep; 122(3):457-63. PubMed ID: 11547294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.